Novel Collagen Membrane Improves Colon-on-a-Chip Functionality
Article May 23, 2018 | By Sonali Karnik, PhD
Inflammatory bowel disorders (IBDs) such as Crohn’s disease are caused by complex interactions between intestinal cells, cytokines, and gut microbiota. Different treatment modalities and drugs for IBDs are less effective in some patients than others. This unpredictability of response to drugs in some patients can be attributed to that person’s unique physiology and gut microenvironment.
For understanding the interactions between intestinal cells and cytokines, there is a need to have efficient physiologic models that can replicate the niche environment of the gut. While rodents are extensively used as animal models for studies involving gut and drug interactions, due to the differences in the rodent and human physiology these animal models do not reflect the complex human gut niche.
Microfluidic tissue-chips can replicate the complex tissue microenvironment and can be engineered according to the testing needs. These tissue systems can be regulated and controlled better when conducting experiments. The existing microfluidic gut-on-a-chip models use either PDMS (Polydimethylsiloxane) or PDMS combined with other synthetic materials such as Poly- L- Lactic Acid (PLLA). Even though these materials have been found to support cell growth, there are some undesired effects observed such as the cells developing a non-physiologic squamous epithelium instead of columnar which is the type observed in vivo. These membranes also have non-physiological pores which span several micrometers restricting cellular movement across the barrier.
Our objective was to build a microfluidic model of colon using natural tissue base matrix or extracellular matrix made from collagen type I to closely mimic the structure and function of the colon and which can be used to study the complex interaction of the cellular components and drug metabolism.
What makes our microfluidic colon-on-a-chip unique is the membrane made from natural base matrix material used to support cells in the device. Using collagen type I instead of a synthetic material replicates the niche environment in the native tissue. We tested our devices with this novel collagen membrane for cell viability, functionality, and mass transport of nutrients across the membrane barrier to see if this membrane improved cellular function when compared to the devices made with commercially available Transwell membranes. Our findings suggest that the devices with collagen type I membrane had better and extended viability of the human gut cells, retention of morphology, function, as well as barrier function.
Our device having two separate chambers with the collagen matrix can be used for co-cultures of different cells with gut cells. We can see our collagen membrane based colon-on-a-chip model as an efficient tool to help to predict the response of gut cells to different effectors such as gut microorganisms, drugs, and cytokines helping in the drug discovery process.
Wang, C., Tanataweethum, N., Karnik, S., & Bhushan, A. (2018). Novel Microfluidic Colon with an Extracellular Matrix Membrane. ACS Biomaterials Science & Engineering, 4(4), 1377-1385. doi:10.1021/acsbiomaterials.7b00883
What if immunotherapy was the solution to cure Alzheimer’s disease (AD)? AD represents a major health issue as it affects an increasing number of people each year. The search for a therapy against AD is uncertain. Nevertheless, we can hope that the fast-growing advances in biotechnologies could lead to an improvement in diagnostics and a better understanding of the disease.READ MORE
A growing number of life science businesses are turning to greater supply chain collaboration for benefits like accelerated time to market, improved quality, reduced risk and more rapid and widespread innovation. But while 68% of executives in this industry say active and meaningful engagement with suppliers is essential to success, far too many, over a third, struggle to implement it.READ MORE
Developments in pharmaceuticals have made new treatments available, enhancing quality of life for patients. Advanced data analytics solutions mean treatments are more effective and affordable, and less intrusive. However, these evolutions will mean major changes in how companies function requiring new capabilities for operations and supply chain.READ MORE